Empori Tablets 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Samik Pharmaceutical Co., Ltd.
MFDS item code 202102083 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in adults with type 2 diabetes. It can be administered alone but may also be taken in combination with metformin or other diabetic medications if blood sugar control is difficult. Specifically, it is added to treatment when metformin alone is insufficient, or when blood sugar control is challenging even during insulin therapy, to enhance therapeutic efficacy. Additionally, it may help with blood sugar control and prevent cardiovascular events in patients with type 2 diabetes who have cardiovascular disease, thus it should be used with caution. This medication can be used flexibly depending on various treatment situations, improving blood sugar management for patients.
The recommended dose of this medicine is 10 mg once daily for monotherapy or as add-on combination therapy with other blood glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered in combination with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special Populations •Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. For patients who tolerate this medicine well but have a persistent eGFR of less than 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose of this medicine should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the eGFR decreases to less than 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be taken into consideration in patients aged 75 years and older. As clinical experience in older adults aged 85 years and older is limited, initiation of treatment with this medicine is not recommended (see Precautions for Use, section 4. General Precautions).
This medication should not be used by certain patients. Firstly, patients allergic to any of the components in this medication should not take it. Secondly, patients with type 1 diabetes or experiencing diabetic ketoacidosis should also avoid using this medication. Thirdly, patients with severely reduced kidney function or end-stage renal disease, as well as those undergoing dialysis, should not take this medication. Fourthly, patients with genetic lactose-related problems should also not use this medication. For patients with slightly reduced kidney function, this medication should be used cautiously. In particular, patients whose glomerular filtration rate falls below a certain threshold may require dosage adjustment or discontinuation. Patients with end-stage renal disease or those on dialysis should not use this medication as its efficacy is not expected. For patients with heart failure, those with mild to moderate cases should use the medication with caution, while severe heart failure patients are advised against using it. Moreover, when taken together with insulin or medications that stimulate insulin secretion, the risk of hypoglycemia may increase, necessitating dosage adjustments for these medications when using this drug. During treatment with this medication, various adverse reactions may occur. The most common adverse reaction is hypoglycemia, which occurs when taken in combination with insulin or sulfonylureas. Symptoms such as genital infections, urinary tract infections, increased urination, and decreased fluid volume have also been reported, so caution is required. Additionally, serious adverse reactions such as ketoacidosis, urosepsis, pyelonephritis, and perineal necrosis have been reported, and immediate consultation with medical staff is necessary if symptoms occur. Elderly patients, especially those over 75 years old, are at higher risk of fluid volume loss, so they should be monitored closely while using this medication. This medication may affect body hydration and lower blood pressure, so patients with a history of hypotension or cardiovascular disease should use it cautiously. Use of this drug is not recommended during pregnancy, and it should be discontinued if pregnancy is confirmed. In breastfeeding cases, as this medication may be secreted in breast milk, it is advisable to stop breastfeeding. The safety and efficacy of this medication in children under the age of 18 have not been established, so it should not be used in pediatric patients. No specific toxic symptoms have been reported in cases of overdose, but in the event of an overdose, immediate medical attention should be sought for appropriate treatment. This medication should be kept out of the reach of children and should not be transferred to other containers for safety. Finally, there is a risk of hypoglycemia while driving or operating machinery during treatment with this medication, so caution is advisable, especially when used together with insulin or sulfonylureas.
Not everyone experiences these, and they can vary from person to person.
This medication must be kept in a tightly sealed container to prevent exposure to air or moisture. It is recommended to store at room temperature between 1 and 30 degrees Celsius.
Pale yellow, double convex, round film-coated tablets
Box - 10 tablets/box [10 tablets/PTP x 1], Box - 30 tablets/box [10 tablets/PTP x 3], Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
Samik Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.